Two complementary Nature Biotechnology reports introduced quantitative in vivo assays that measure endosomal escape of lipid nanoparticles (LNPs) in animal models, providing actionable readouts to optimize liver-targeted RNA delivery. Researchers used lysosomal barcoding and other in vivo quantification strategies to show how branched ionizable lipids and formulation variables control cytosolic release of therapeutic cargo. The papers present head-to-head data linking chemical design of ionizable lipids to functional endosomal escape and potency in hepatocytes. Authors highlight that prior in vitro screens poorly predict in vivo escape and that these new assays can prioritize lead lipids and formulations before costly preclinical pipelines. Biotech companies racing to deploy mRNA and gene-editing therapies are expected to adopt these assays to de-risk candidate selection and improve therapeutic index. The studies supply a mechanistic path to increase LNP efficiency and reduce required doses for systemic gene therapies and vaccines.